Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Antitrust Law (1)
- Competition Law (1)
- EU Treaty Rules (1)
- Energy Law (1)
- Essential Facilities (1)
-
- Essential Facilities Doctrine (1)
- European Law (1)
- Evergreening (1)
- Forced Sharing (1)
- Generic medicines (1)
- Hierarch of Rules (1)
- Incentives to Invest (1)
- Innovation (1)
- Intellectual monopoly privileges (1)
- Internal Energy Market (1)
- Long-term Competition (1)
- Market Definition (1)
- Patented pharmaceuticals (1)
- Pharmaceutical Benefits Scheme (1)
- Public Policy and New Technologies in Trade and Investment Agreements (1)
- Reference pricing (1)
- Refusal to Deal (1)
- Sector Rules (1)
- Third Party Access (1)
- Trade agreements (1)
- Publication
Articles 1 - 2 of 2
Full-Text Articles in Medical Jurisprudence
Third Party Access And Refusal To Deal In European Energy Networks: How Sector Regulation And Competition Law Meet Each Other, Michael Diathesopoulos
Third Party Access And Refusal To Deal In European Energy Networks: How Sector Regulation And Competition Law Meet Each Other, Michael Diathesopoulos
Michael Diathesopoulos
In this paper, we will analyse the issue of concurrence between competition and sector rules and the relation between parallel concepts within the two different legal frameworks. We will firstly examine Third Party Access in relation to essential facilities doctrine and refusal of access and we will identify the common points and objectives of these concepts and the extent to which they provide a context to each other’s implementation. Second, we will focus on how Commission uses sector regulation and objectives as a context within the process of implementation of competition law in the energy sector and third, we will …
Impact Of The Australia-Us Free Trade Agreement On Australian Medicines Regulation And Prices, Thomas A. Faunce, James Bai, Duy Nguyen
Impact Of The Australia-Us Free Trade Agreement On Australian Medicines Regulation And Prices, Thomas A. Faunce, James Bai, Duy Nguyen
Thomas A Faunce
The Australia – United States Free Trade Agreement (AUSFTA) came into force on 1 January 2005. Before and subsequently to the AUSFTA being concluded, controversy surrounded the debate over its impact on Australia ’ s health policy, specifically on regulation of pharmaceutical patents and Australia ’ s cost-effectiveness system relating to prescription medicine prices known as the Pharmaceutical Benefits Scheme (PBS). This article examines the expectations of both parties in the pharmaceutical sector with regard to the AUSFTA, as well as how successfully they were achieved. It seeks to analyse important relevant outcomes for regulators, the public and pharmaceutical industry, …